Next Article in Journal
Polymorphisms of Mismatch Repair Pathway Genes Predict Clinical Outcomes in Oral Squamous Cell Carcinoma Patients Receiving Adjuvant Concurrent Chemoradiotherapy
Next Article in Special Issue
Oncogenic Signaling in Tumorigenesis and Applications of siRNA Nanotherapeutics in Breast Cancer
Previous Article in Journal
Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer
Previous Article in Special Issue
Antitumor Effects of Intra-Arterial Delivery of Albumin-Doxorubicin Nanoparticle Conjugated Microbubbles Combined with Ultrasound-Targeted Microbubble Activation on VX2 Rabbit Liver Tumors
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessFeature PaperReview

Recent Progress in the Theranostics Application of Nanomedicine in Lung Cancer

1
Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, Providence Saint John’s Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
2
Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, The University of California, Los Angeles (UCLA) Factor Bldg. 10-240, 621 Charles E. Young Dr., Los Angeles, CA 90095, USA
3
Department of Bioengineering, Rice University, 6500 Main Street, Houston, TX 77005, USA
*
Authors to whom correspondence should be addressed.
Cancers 2019, 11(5), 597; https://doi.org/10.3390/cancers11050597
Received: 30 March 2019 / Revised: 27 April 2019 / Accepted: 27 April 2019 / Published: 29 April 2019
(This article belongs to the Special Issue Cancer Nanomedicine)
  |  
PDF [1828 KB, uploaded 29 April 2019]
  |     |  

Abstract

Lung cancer is one of the leading causes of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) causes around 80% to 90% of deaths. The lack of an early diagnosis and inefficiency in conventional therapies causes poor prognosis and overall survival of lung cancer patients. Recent progress in nanomedicine has encouraged the development of an alternative theranostics strategy using nanotechnology. The interesting physico-chemical properties in the nanoscale have generated immense advantages for nanoparticulate systems for the early detection and active delivery of drugs for a better theranostics strategy for lung cancer. This present review provides a detailed overview of the recent progress in the theranostics application of nanoparticles including liposomes, polymeric, metal and bio-nanoparticles. Further, we summarize the advantages and disadvantages of each approach considering the improvement for the lung cancer theranostics. View Full-Text
Keywords: lung cancer; nanomedicine; theranostics; clinical status; cancer therapy lung cancer; nanomedicine; theranostics; clinical status; cancer therapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Mukherjee, A.; Paul, M.; Mukherjee, S. Recent Progress in the Theranostics Application of Nanomedicine in Lung Cancer. Cancers 2019, 11, 597.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top